Skip to main content

View full-text article in PMC

. 2020 Oct 30;11:575009. doi: 10.3389/fphar.2020.575009

TABLE 3.

2-years survival, 95% confidence intervals and log-rank test for EFS and OS for all variables analyzed. First CR patients only.

		n	EFS				OS
		n	2-year survival	95% CI		p-value	2-year survival	95% CI		p-value
	All patients	44	60.7	44.9	82.0	—	80.2	65.1	98.8	—
Gender	Female	19	44.9	24.6	82.1	0.056	79.5	60.2	100.0	0.60
Gender	Male	25	74.0	55.1	99.2	0.056	79.5	57.7	100.0	0.60
Age at diagnosis	< 1.6 years	5	80.0	51.6	100.0	0.48	100.0	100.0	100.0	0.26
Age at diagnosis	≥ 1.6 years	39	57.2	40.0	81.8	0.48	76.5	59.3	98.8	0.26
MYCN	Amplified	10	60.0	36.2	99.5	0.58	56.3	27.9	100.0	0.12
MYCN	Not Amplified	34	61.6	43.5	87.2	0.58	89.6	75.8	100.0	0.12
Cycles	5 or less	10	45.0	21.1	96.1	0.36	90.0	73.2	100.0	0.73
Cycles	More than 5	34	68.6	52.2	90.0	0.36	72.1	50.9	100.0	0.73
Previous ASCT	No	33	58.7	39.9	86.3	0.48	85.4	69.5	100.0	0.63
Previous ASCT	Yes	11	65.5	38.9	100.0	0.48	71.4	44.7	100.0	0.63
Previous RT	No	23	63.1	40.7	97.8	0.58	95.7	87.7	100.0	0.37
Previous RT	Yes	21	58.3	39.1	87.0	0.58	69.8	48.4	100.0	0.37
MRD	No	38	58.9	41.4	83.8	0.87	77.5	61.0	98.6	0.38
MRD	Yes	6	66.7	37.9	100.0	0.87	100.0	100.0	100.0	0.38